Loading search results

Outcome Measures

Primary Outcomes (5)

The number of patients with somatic BRCA mutations compared to number of patients without somatic BRCA mutations
4 years
The number of patients with homologous recombination repair deficiencies compared to the number of patients that do not have homologous recombination repair deficiencies.
4 years
The number and types of mutated genes.
4 years
The number of patients with antibodies to the study drug
4 years
Evaluate the levels of PI3K/Akt pathway expression per patient
4 years

Secondary Outcomes (4)

HRR deficiency profile
4 years
Level of poly (ADP-ribose) (PAR) expression
4 years
Signature of PARP response compared with signature of platinum sensitivity
4 years
Signature of PARP response and PARP resistance on different tumour sites
4 years

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Epithelial ovarian cancer (including fallopian tube or peritoneal cancer) patients that are or had received treatment with Olaparib.

You may qualify if:

Previous or current treatment with Olaparib in a clinical trial/standard of care that included one of the following as a first step study for epithelial ovarian cancer (including fallopian tube or peritoneal cancer):

Study Sites (8)

South Eastern Sydney Local Health District

Randwick, New South Wales, 2031, Australia

British Columbia Cancer Centre

Vancouver, British Columbia, V5Z 4E6, Canada

Ottawa Hospital Research Institute

Ottawa, Ontario, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

Institute of European Oncology

Milan, Italy

Vall d'Hebron

Barcelona, Spain

The Royal Marsden

Sutton, England, SM2 5PT, United Kingdom

Biospecimen

Retention: SAMPLES WITH DNA

* Archival tumor tissue sample for biomarker research * Optional fresh tumor tissue sample for biomarker research (if participants are still on olaparib and their disease progressed) * Blood sample for pharmacokinetics (if participants are still on olaparib) * Blood sample for pharmacogenomics (if participants are still on olaparib and their disease progressed) * Blood samples for circulating tumor DNA (if participants are still on olaparib) * Blood sample for germline BRCA1/2 testing if not previously done (if participants are still on olaparib and their disease progressed)

MeSH Terms

Conditions

Carcinoma, Ovarian EpithelialFallopian Tube Neoplasms

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsOvarian NeoplasmsEndocrine Gland NeoplasmsNeoplasms by SiteOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

A Study of Long-Term Responders on Olaparib

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (5)

Secondary Outcomes (4)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (8)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (5)

Secondary Outcomes (4)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (8)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations